MCID: JVN004
MIFTS: 70

Juvenile Myelomonocytic Leukemia

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Juvenile Myelomonocytic Leukemia

MalaCards integrated aliases for Juvenile Myelomonocytic Leukemia:

Name: Juvenile Myelomonocytic Leukemia 53 37 12 49 55 28 51 14 69
Leukemia, Juvenile Myelomonocytic 53 49 71 13
Jmml 53 49 55 71
Leukemia, Juvenile Myelomonocytic, Somatic 53
Juvenile Chronic Myelomonocytic Leukemia 55
Juvenile Chronic Myelogenous Leukemia 71
Leukemia, Myelomonocytic, Juvenile 41

Characteristics:

Orphanet epidemiological data:

55
juvenile myelomonocytic leukemia
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood,Infancy;

OMIM:

53
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
one family has been reported with germline cbl mutation (last curated may 2016)


HPO:

31
juvenile myelomonocytic leukemia:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

OMIM 53 607785
Disease Ontology 12 DOID:0050458
ICD10 32 C93.3 C93.30
MeSH 41 D054429
NCIt 46 C9233
Orphanet 55 ORPHA86834
MESH via Orphanet 42 D054429
UMLS via Orphanet 70 C0349639
ICD10 via Orphanet 33 C93.3
SNOMED-CT via HPO 65 263681008 124975008
UMLS 69 C0349639

Summaries for Juvenile Myelomonocytic Leukemia

OMIM : 53 Juvenile myelomonocytic leukemia is an aggressive pediatric myelodysplastic syndrome (MDS)/myeloproliferative disorder (MPD) characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny (Loh et al., 2009). JMML constitutes approximately 30% of childhood cases of myelodysplastic syndrome and 2% of leukemia (Hasle et al., 1999). Although JMML is a progressive and often rapidly fatal disease without hematopoietic stem cell transplantation (HSCT), some patients have been shown to have a prolonged and stable clinical course without HSCT (Niemeyer et al., 1997). Chronic myelomonocytic leukemia (CMML) is a similar disorder with later onset. Both JMML and CMML have a high frequency of mutations affecting the RAS signaling pathway and show hypersensitivity to stimulation with GM-CSF, which causes STAT5 (601511) hyperphosphorylation (Loh et al., 2009). (607785)

MalaCards based summary : Juvenile Myelomonocytic Leukemia, also known as leukemia, juvenile myelomonocytic, is related to myelodysplastic myeloproliferative cancer and leukemia, and has symptoms including fever, fatigue and exanthema. An important gene associated with Juvenile Myelomonocytic Leukemia is PTPN11 (Protein Tyrosine Phosphatase, Non-Receptor Type 11), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

NIH Rare Diseases : 49 This condition doesn't have a summary yet. Please see our page(s) on Myelodysplastic/myeloproliferative disease.

UniProtKB/Swiss-Prot : 71 Leukemia, juvenile myelomonocytic: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

Wikipedia : 72 Juvenile myelomonocytic leukemia (JMML) is a serious chronic leukemia (cancer of the blood) that affects... more...

Related Diseases for Juvenile Myelomonocytic Leukemia

Diseases in the Chronic Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Diseases related to Juvenile Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic myeloproliferative cancer 32.0 CSF2 NF1 NRAS PTPN11 SETBP1 TET2
2 leukemia 31.6 CSF2 FLT3 NRAS PTPN11 RAF1 RUNX1
3 neurofibromatosis, type iv, of riccardi 31.2 KRAS NF1 PTPN11
4 noonan syndrome 1 31.1 BRAF KRAS NF1 NRAS PTPN11 RAF1
5 chronic myelomonocytic leukemia 30.5 FLT3 RUNX1 SETBP1 TET2
6 myeloid leukemia 30.3 CSF2 FLT3 PTPN11 RUNX1 TET2
7 leukemia, chronic myeloid 30.0 CSF2 FLT3 NRAS RUNX1 SETBP1
8 myelodysplastic syndrome 29.9 ARHGAP26 CSF2 FLT3 KRAS NF1 NRAS
9 leukemia, acute myeloid 29.0 CSF2 FLT3 KRAS MLLT11 NRAS PTPN11
10 noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia 12.6
11 noonan syndrome 3 11.2
12 noonan syndrome 4 11.2
13 noonan syndrome 5 11.2
14 noonan syndrome 6 11.2
15 noonan syndrome 7 11.2
16 noonan syndrome 8 11.2
17 noonan syndrome 9 11.2
18 noonan syndrome 10 11.2
19 schimmelpenning-feuerstein-mims syndrome 10.6 KRAS NRAS
20 villonodular synovitis 10.5 PTPN11 SOS1
21 noonan syndrome with multiple lentigines 10.5 BRAF PTPN11 RAF1
22 costello syndrome 10.5 KRAS PTPN11 SOS1
23 hyperplastic polyposis syndrome 10.5 BRAF KRAS
24 refractory anemia with excess blasts 10.5 SETBP1 TET2
25 autosomal dominant café au lait spots 10.5 NF1 PTPN11 SPRED1
26 hypertelorism 10.5 BRAF PTPN11 RAF1
27 neurofibromatosis-noonan syndrome 10.5 NF1 PTPN11
28 differentiated thyroid carcinoma 10.5 BRAF KRAS NRAS
29 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.5 FLT3 RUNX1
30 lentigines 10.5 BRAF PTPN11 RAF1
31 pulmonary valve stenosis 10.4 PTPN11 SOS1 SPRED1
32 legius syndrome 10.4 NF1 PTPN11 SPRED1
33 pulmonary valve disease 10.4 PTPN11 SOS1 SPRED1
34 tumor suppressor gene on chromosome 11 10.4 BRAF KRAS
35 neutrophilia, hereditary 10.4 CSF2 FLT3
36 hematopoietic stem cell transplantation 10.4
37 pseudo-turner syndrome 10.4
38 st. louis encephalitis 10.4 KRAS RAF1
39 pulmonic stenosis 10.3 BRAF KRAS NF1 PTPN11 RAF1
40 pilocytic astrocytoma of cerebellum 10.3 BRAF NF1
41 core binding factor acute myeloid leukemia 10.3 CBL FLT3 KRAS NRAS RUNX1
42 cardiofaciocutaneous syndrome 1 10.2 BRAF KRAS PTPN11 SOS1 SPRED1
43 leopard syndrome 10.2 BRAF NF1 PTPN11 RAF1 SPRED1
44 pilocytic astrocytoma 10.2 BRAF KRAS NF1 NRAS PTPN11 RAF1
45 hematologic cancer 10.2 CSF2 FLT3 PTPN11 RUNX1
46 bone marrow cancer 10.2 CSF2 FLT3 NF1 PTPN11 RUNX1
47 lymphoblastic leukemia 10.2
48 juvenile xanthogranuloma 10.2
49 cytomegalovirus infection 10.2
50 syringocystadenoma papilliferum 10.1 BRAF KRAS

Graphical network of the top 20 diseases related to Juvenile Myelomonocytic Leukemia:



Diseases related to Juvenile Myelomonocytic Leukemia

Symptoms & Phenotypes for Juvenile Myelomonocytic Leukemia

Symptoms via clinical synopsis from OMIM:

53
Hematology:
juvenile myelomonocytic leukemia


Clinical features from OMIM:

607785

Human phenotypes related to Juvenile Myelomonocytic Leukemia:

31
# Description HPO Frequency HPO Source Accession
1 juvenile myelomonocytic leukemia 31 HP:0012209

UMLS symptoms related to Juvenile Myelomonocytic Leukemia:


fever, fatigue, exanthema

GenomeRNAi Phenotypes related to Juvenile Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

25 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.11 KRAS
2 Decreased viability GR00106-A-0 10.11 KRAS
3 Decreased viability GR00173-A 10.11 FLT3
4 Decreased viability GR00221-A-1 10.11 FLT3 KRAS NF1 NRAS RAF1
5 Decreased viability GR00221-A-2 10.11 KRAS NF1 RAF1
6 Decreased viability GR00221-A-3 10.11 NRAS
7 Decreased viability GR00221-A-4 10.11 FLT3 NF1
8 Decreased viability GR00231-A 10.11 RAF1
9 Decreased viability GR00301-A 10.11 KRAS RAF1
10 Decreased viability GR00381-A-1 10.11 KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.94 SOS1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.94 BRAF
13 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.94 PTPN11
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.94 SOS1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.94 PTPN11
16 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.94 CBL
17 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.94 SOS1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.94 CBL SOS1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.94 PTPN11
20 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.94 PTPN11 RAF1 BRAF NF1 CBL SOS1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.94 CBL RAF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.94 RAF1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.94 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.94 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.94 PTPN11
26 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.94 CBL
27 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.94 PTPN11
28 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.94 BRAF
29 Increased shRNA abundance (Z-score > 2) GR00366-A-201 9.94 CBL
30 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.94 CBL
31 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.94 BRAF
32 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.94 BRAF
33 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.94 BRAF
34 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.94 PTPN11
35 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.94 CBL
36 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.94 NF1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.94 PTPN11 BRAF
38 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.94 RAF1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.94 PTPN11
40 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.94 NF1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.94 PTPN11
42 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.94 CBL
43 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.94 NF1
44 Decreased cell migration GR00055-A-1 9.73 CBL KRAS ARHGAP26 NF1 BRAF SOS1
45 Increased cell migration GR00055-A-3 9.35 CBL KRAS NF1 BRAF SOS1

MGI Mouse Phenotypes related to Juvenile Myelomonocytic Leukemia:

43 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 NF1 KRAS NRAS RAF1 RIT1 PTPN11
2 hematopoietic system MP:0005397 10.39 NF1 KRAS NRAS PTPN11 RRAS RUNX1
3 cardiovascular system MP:0005385 10.36 NF1 KRAS NRAS RAF1 PTPN11 RRAS
4 growth/size/body region MP:0005378 10.35 NRAS FLT3 NF1 KRAS RUNX1 RAF1
5 immune system MP:0005387 10.35 NF1 KRAS NRAS PTPN11 RRAS RUNX1
6 homeostasis/metabolism MP:0005376 10.34 NF1 KRAS NRAS RUNX1 RAF1 PTPN11
7 endocrine/exocrine gland MP:0005379 10.33 NF1 KRAS NRAS PTPN11 RUNX1 RAF1
8 craniofacial MP:0005382 10.27 NF1 KRAS NRAS PTPN11 RAF1 BRAF
9 mortality/aging MP:0010768 10.25 NRAS FLT3 NF1 KRAS RUNX1 RAF1
10 embryo MP:0005380 10.21 NRAS NF1 KRAS RAF1 PTPN11 BRAF
11 integument MP:0010771 10.2 NF1 KRAS NRAS RAF1 PTPN11 RUNX1
12 neoplasm MP:0002006 10.1 KRAS NRAS NF1 PTPN11 RRAS RUNX1
13 liver/biliary system MP:0005370 10.09 NF1 KRAS NRAS RAF1 PTPN11 RUNX1
14 hearing/vestibular/ear MP:0005377 10 NF1 KRAS RAF1 PTPN11 CBL BRAF
15 muscle MP:0005369 9.97 NF1 KRAS RAF1 PTPN11 CBL BRAF
16 no phenotypic analysis MP:0003012 9.86 NRAS FLT3 KRAS RAF1 PTPN11 RUNX1
17 pigmentation MP:0001186 9.63 NF1 KRAS NRAS PTPN11 BRAF CBL
18 respiratory system MP:0005388 9.61 NF1 KRAS RAF1 PTPN11 RUNX1 BRAF
19 skeleton MP:0005390 9.36 NF1 KRAS NRAS RAF1 PTPN11 RUNX1

Drugs & Therapeutics for Juvenile Myelomonocytic Leukemia

Drugs for Juvenile Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 402)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
6
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
7
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
8
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
11
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
12
Ofloxacin Approved Phase 3 82419-36-1 4583
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Idarubicin Approved Phase 3,Phase 1,Phase 2 58957-92-9 42890
15
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
16
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
17
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
18
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 83-43-2 6741
19
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 50-24-8 5755
20
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
21
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
22
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
23
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
24
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
25
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
26 Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
27
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
28
Asparaginase Approved, Investigational Phase 3 9015-68-3
29
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
30
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 657311 5754
31
Thioguanine Approved Phase 3 154-42-7 2723601
32
Aldesleukin Approved Phase 3,Phase 1,Phase 2 110942-02-4, 85898-30-2
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
34
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
35
Ephedrine Approved Phase 3 299-42-3 9294
36
Pseudoephedrine Approved Phase 3 90-82-4 7028
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Dalteparin Approved Phase 3 9005-49-6
39
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
40
Ondansetron Approved Phase 3,Phase 2,Phase 1 99614-02-5 4595
41
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
42
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
43
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
44
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
45
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
46
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
47
Morphine Approved, Investigational Phase 3 57-27-2 5288826
48
Allopurinol Approved Phase 3,Phase 2,Phase 1 315-30-0 2094
49
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
50
Iron Approved Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 455)

# Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
3 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
7 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
8 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
9 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
10 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
13 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
14 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
15 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
17 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
18 Decitabine Versus Supportive Care in Adults With Advanced-stage MDS Completed NCT00043381 Phase 3 decitabine (5-aza-2'deoxycytidine)
19 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
20 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
21 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
22 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
25 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
26 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
27 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
28 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
29 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
30 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
31 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
32 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
33 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
34 Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
35 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Recruiting NCT02907359 Phase 3 Guadecitabine
36 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
37 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Active, not recruiting NCT01757535 Phase 3 300 mg Oral Azacitidine;Placebo
38 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
39 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
40 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
41 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
42 Phase 3 Study of ASTX727 vs IV Decitabine in MDS and CMML Not yet recruiting NCT03306264 Phase 3 ASTX727;Dacogen
43 Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Terminated NCT00109538 Phase 3 Lonafarnib
44 Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
45 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
46 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
47 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
48 Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid
49 Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure Unknown status NCT01133886 Phase 2 Decitabine
50 A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q Unknown status NCT00885508 Phase 2 Lenalidomide

Search NIH Clinical Center for Juvenile Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Juvenile Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Juvenile Myelomonocytic Leukemia:
Hemacord
Embryonic/Adult Cultured Cells Related to Juvenile Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244

Cochrane evidence based reviews: leukemia, myelomonocytic, juvenile

Genetic Tests for Juvenile Myelomonocytic Leukemia

Genetic tests related to Juvenile Myelomonocytic Leukemia:

# Genetic test Affiliating Genes
1 Juvenile Myelomonocytic Leukemia 28 ARHGAP26 CBL MLLT11 NF1 PTPN11

Anatomical Context for Juvenile Myelomonocytic Leukemia

MalaCards organs/tissues related to Juvenile Myelomonocytic Leukemia:

38
Myeloid, Bone, Bone Marrow, T Cells, Lymph Node, Kidney, Liver

Publications for Juvenile Myelomonocytic Leukemia

Articles related to Juvenile Myelomonocytic Leukemia:

(show top 50) (show all 252)
# Title Authors Year
1
Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. ( 29279013 )
2018
2
Integrated molecular profiling of juvenile myelomonocytic leukemia. ( 29437595 )
2018
3
Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. ( 29316027 )
2018
4
Juvenile myelomonocytic leukemia presenting as bilateral breast masses. ( 27717995 )
2017
5
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome. ( 28098151 )
2017
6
Juvenile myelomonocytic leukemia in an infant with congenital human immunodeficiency virus and cytomegalovirus infection. ( 28612348 )
2017
7
Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. ( 29259179 )
2017
8
Diagnostic considerations in juvenile myelomonocytic leukemia in tropical settings. ( 28263030 )
2017
9
Association Between Juvenile Myelomonocytic Leukemia, Juvenile Xanthogranulomas and Neurofibromatosis Type 1: Case Report and Review of the Literature. ( 28111791 )
2017
10
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. ( 29259247 )
2017
11
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. ( 29129488 )
2017
12
Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of 65 Patients. ( 28179213 )
2017
13
Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report. ( 28959694 )
2017
14
Juvenile Myelomonocytic Leukemia: Profile and Outcome. ( 28755173 )
2017
15
Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7. ( 28084675 )
2017
16
Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. ( 27748021 )
2017
17
Juvenile myelomonocytic leukemia with prominent CD141 myeloid dendritic cell differentiation. ( 28414089 )
2017
18
Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic KRAS. ( 28244637 )
2017
19
Epigenetic dysregulation of the erythropoietic transcription factor KLF1 and the I^-like globin locus in juvenile myelomonocytic leukemia. ( 28749240 )
2017
20
Complete Resolution of Lymphoid Interstitial Pneumonia in a Patient With Juvenile Myelomonocytic Leukemia Treated With Allogeneic Bone Marrow Transplant: Killing 2 Birds With 1 Stone. ( 29023302 )
2017
21
LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. ( 26712910 )
2016
22
Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy. ( 26911351 )
2016
23
Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia. ( 26891149 )
2016
24
Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia. ( 26983639 )
2016
25
Diagnosis and treatment of juvenile myelomonocytic leukemia. ( 27322988 )
2016
26
MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. ( 27447965 )
2016
27
Molluscum Mimicker: Juvenile Xanthogranulomas with Associated Juvenile Myelomonocytic Leukemia. ( 27514241 )
2016
28
Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. ( 27145535 )
2016
29
Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia. ( 26757980 )
2016
30
Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. ( 26980750 )
2016
31
Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC). ( 27184944 )
2016
32
CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia. ( 27158276 )
2016
33
Juvenile myelomonocytic leukemia. ( 25435114 )
2015
34
How I treat juvenile myelomonocytic leukemia. ( 25564399 )
2015
35
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan. ( 25504334 )
2015
36
Neurofibromatosis type 1 diagnosed in a child based on multiple juvenile xanthogranulomas and juvenile myelomonocytic leukemia. ( 25516272 )
2015
37
Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family. ( 25939664 )
2015
38
Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. ( 25838281 )
2015
39
Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. ( 26457648 )
2015
40
Generalized lichen nitidus associated with neurofibromatosis type 1 and juvenile myelomonocytic leukemia. ( 26341890 )
2015
41
Neutrophilic figurate erythema of infancy associated with juvenile myelomonocytic leukemia. ( 25623543 )
2015
42
Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. ( 25552679 )
2015
43
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. ( 25704135 )
2015
44
Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl. ( 26181421 )
2015
45
Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. ( 24578498 )
2014
46
Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. ( 24734223 )
2014
47
Aggressive congenital juvenile myelomonocytic leukemia associated with somatic KRAS p.G13D mutation and concurrent germline IGF1R duplication. ( 25110823 )
2014
48
Concurrent juvenile myelomonocytic leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS. ( 24610751 )
2014
49
Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia. ( 24766281 )
2014
50
Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation. ( 25047104 )
2014

Variations for Juvenile Myelomonocytic Leukemia

UniProtKB/Swiss-Prot genetic disease variations for Juvenile Myelomonocytic Leukemia:

71 (show all 18)
# Symbol AA change Variation ID SNP ID
1 ARHGAP26 p.Asn417Ser VAR_013623 rs121918546
2 KRAS p.Gly12Asp VAR_016026 rs121913529
3 KRAS p.Gly12Ser VAR_016028 rs121913530
4 KRAS p.Gly13Asp VAR_016029 rs112445441
5 NRAS p.Gly13Asp VAR_063084 rs121434596
6 NRAS p.Gly12Asp VAR_071129 rs121913237
7 PTPN11 p.Asp61Val VAR_015991 rs121918461
8 PTPN11 p.Asp61Tyr VAR_015992 rs397507510
9 PTPN11 p.Glu69Lys VAR_015993 rs397507511
10 PTPN11 p.Ala72Thr VAR_015996 rs121918453
11 PTPN11 p.Ala72Val VAR_015997 rs121918454
12 PTPN11 p.Glu76Ala VAR_015998 rs121918465
13 PTPN11 p.Glu76Gly VAR_015999 rs121918465
14 PTPN11 p.Glu76Lys VAR_016000 rs121918464
15 PTPN11 p.Glu76Val VAR_016001 rs121918465
16 PTPN11 p.Gly507Ala VAR_016002 rs397507546
17 PTPN11 p.Gly507Arg VAR_016003 rs397507545
18 SETBP1 p.Asp868Asn VAR_063807 rs267607042

ClinVar genetic disease variations for Juvenile Myelomonocytic Leukemia:

6 (show all 30)
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
2 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
3 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
4 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
5 PTPN11 NM_002834.4(PTPN11): c.215C> G (p.Ala72Gly) single nucleotide variant Pathogenic rs121918454 GRCh37 Chromosome 12, 112888199: 112888199
6 PTPN11 NM_002834.4(PTPN11): c.922A> G (p.Asn308Asp) single nucleotide variant Pathogenic rs28933386 GRCh37 Chromosome 12, 112915523: 112915523
7 PTPN11 NM_002834.4(PTPN11): c.923A> G (p.Asn308Ser) single nucleotide variant Pathogenic rs121918455 GRCh37 Chromosome 12, 112915524: 112915524
8 PTPN11 NM_002834.4(PTPN11): c.1403C> T (p.Thr468Met) single nucleotide variant Pathogenic rs121918457 GRCh37 Chromosome 12, 112926270: 112926270
9 PTPN11 NM_002834.4(PTPN11): c.188A> G (p.Tyr63Cys) single nucleotide variant Pathogenic rs121918459 GRCh37 Chromosome 12, 112888172: 112888172
10 PTPN11 NM_002834.4(PTPN11): c.218C> T (p.Thr73Ile) single nucleotide variant Pathogenic rs121918462 GRCh37 Chromosome 12, 112888202: 112888202
11 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
12 PTPN11 NM_002834.4(PTPN11): c.227A> T (p.Glu76Val) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
13 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
14 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
15 PTPN11 NM_002834.4(PTPN11): c.236A> G (p.Gln79Arg) single nucleotide variant Pathogenic rs121918466 GRCh37 Chromosome 12, 112888220: 112888220
16 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
17 CBL NM_005188.3(CBL): c.1112A> G (p.Tyr371Cys) single nucleotide variant Pathogenic rs387906666 GRCh37 Chromosome 11, 119148892: 119148892
18 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
19 PTPN11 NM_002834.4(PTPN11): c.174C> G (p.Asn58Lys) single nucleotide variant Pathogenic/Likely pathogenic rs397507506 GRCh37 Chromosome 12, 112888158: 112888158
20 PTPN11 NM_002834.4(PTPN11): c.417G> C (p.Glu139Asp) single nucleotide variant Pathogenic rs397507520 GRCh37 Chromosome 12, 112891083: 112891083
21 PTPN11 NM_002834.4(PTPN11): c.1507G> C (p.Gly503Arg) single nucleotide variant Pathogenic rs397507545 GRCh37 Chromosome 12, 112926887: 112926887
22 CBL NM_005188.3(CBL): c.1228-2A> G single nucleotide variant Pathogenic/Likely pathogenic rs727504426 GRCh37 Chromosome 11, 119149218: 119149218
23 NF1 NM_001042492.2(NF1): c.7909C> T (p.Arg2637Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786201367 GRCh37 Chromosome 17, 29684326: 29684326
24 NF1 NM_000267.3(NF1): c.4614G> A (p.Trp1538Ter) single nucleotide variant Pathogenic rs137854555 GRCh37 Chromosome 17, 29588828: 29588828
25 NF1 NF1, IVS34, G-A, +18 single nucleotide variant Pathogenic
26 NF1 NM_000267.3(NF1): c.1642-8A> G single nucleotide variant Pathogenic rs267606602 GRCh37 Chromosome 17, 29548860: 29548860
27 ARHGAP26 NM_015071.5(ARHGAP26): c.1250A> G (p.Asn417Ser) single nucleotide variant Pathogenic rs121918546 GRCh37 Chromosome 5, 142421420: 142421420
28 ARHGAP26 ARHGAP26, 52-BP INS insertion Pathogenic
29 ARHGAP26 ARHGAP26, 74-BP INS insertion Pathogenic
30 PTPN11 NM_002834.4(PTPN11): c.181G> T (p.Asp61Tyr) single nucleotide variant Pathogenic rs397507510 GRCh38 Chromosome 12, 112450361: 112450361

Expression for Juvenile Myelomonocytic Leukemia

Search GEO for disease gene expression data for Juvenile Myelomonocytic Leukemia.

Pathways for Juvenile Myelomonocytic Leukemia

Pathways related to Juvenile Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 BRAF CBL CSF2 FLT3 KRAS NF1
2
Show member pathways
13.65 BRAF CBL FLT3 KRAS NRAS PTPN11
3
Show member pathways
13.61 BRAF CSF2 KRAS NF1 NRAS PTPN11
4
Show member pathways
13.45 ARHGAP26 BRAF KRAS NRAS RAF1 RRAS
5
Show member pathways
13.43 BRAF CBL CSF2 FLT3 KRAS NF1
6
Show member pathways
13.39 BRAF CBL FLT3 KRAS NRAS RAF1
7
Show member pathways
13.32 BRAF CBL KRAS NRAS RAF1 RRAS
8
Show member pathways
13.16 BRAF KRAS NRAS RAF1 RRAS SOS1
9
Show member pathways
13.13 BRAF KRAS NRAS RAF1 RRAS SOS1
10
Show member pathways
13.11 BRAF CBL KRAS NRAS RAF1 RRAS
11
Show member pathways
13.1 BRAF CBL CSF2 FLT3 KRAS NF1
12
Show member pathways
13.02 BRAF CBL KRAS NRAS PTPN11 RAF1
13
Show member pathways
13.01 BRAF KRAS NRAS RAF1 RRAS SOS1
14
Show member pathways
12.99 BRAF KRAS NRAS RAF1 RRAS SOS1
15
Show member pathways
12.99 BRAF CBL KRAS NRAS RAF1 SOS1
16 12.94 BRAF CBL FLT3 KRAS NRAS RAF1
17
Show member pathways
12.93 BRAF CBL KRAS NRAS RAF1 RRAS
18
Show member pathways
12.9 BRAF KRAS NRAS RAF1 SPRED1
19
Show member pathways
12.9 BRAF CBL KRAS PTPN11 RAF1 S